Loading...
Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study
BACKGROUND: Neoadjuvant trials conducted using a double HER2 blockade with lapatinib and trastuzumab, combined with different paclitaxel-containing chemotherapy regimens, have shown high pathological complete response (pCR) rates, but at the cost of important toxicity. We hypothesised that this toxi...
Na minha lista:
| Udgivet i: | Ann Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Oxford University Press
2015
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4304382/ https://ncbi.nlm.nih.gov/pubmed/25467016 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdu551 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|